ReviewCurrent molecular pharmacology2009
Mood-stabilizers target the brain arachidonic acid cascade.
Review in Current molecular pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02272010 (Targeted Alterations in n-3 and n-6 Fatty Acids for the Management of Mood Variability in the Maintenance Phase of Bipolar Disorder), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Targeted Alterations in n-3 and n-6 Fatty Acids for the Management of Mood Variability in the Maintenance Phase of Bipolar Disorder
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Pooled it
- Adjunctive dietary intervention for bipolar disorder: a randomized, controlled, parallel-group, modified double-blinded trial of a high n-3 plus low n-6 diet.Bipolar disorders · 2022Trial
- Gram-negative bacteria-driven increase of cytosolic phospholipase A2 leads to activation of Kupffer cells.Cellular and molecular life sciences : CMLS · 2024Article
- Update on Fatty Acids and the Brain.Nutrients · 2024Article
- New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview.Pharmacological reviews · 2024Review
- Global Neuropsychopharmacological Prescription Trends in Adults with Schizophrenia, Clinical Correlates and Implications for Practice: A Scoping Review.Brain sciences · 2023Article
- Anti-Inflammatory Therapy as a Promising Target in Neuropsychiatric Disorders.Advances in experimental medicine and biology · 2023Review
- New Pharmacological Interventions in Bipolar Disorder.Current topics in behavioral neurosciences · 2021Review
- Cyclooxygenase Inhibition Safety and Efficacy in Inflammation-Based Psychiatric Disorders.Molecules (Basel, Switzerland) · 2020Review
- Comorbid Bipolar Disorder and Migraine: From Mechanisms to Treatment.Frontiers in psychiatry · 2020Review
- Investigation of common, low-frequency and rare genome-wide variation in anorexia nervosa.Molecular psychiatry · 2018Article
- Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice.Bipolar disorders · 2015Article
- Valnoctamide, a non-teratogenic amide derivative of valproic acid, inhibits arachidonic acid activation in vitro by recombinant acyl-CoA synthetase-4.Bipolar disorders · 2014Article
- Docosahexaenoic acid supplementation during pregnancy: a potential tool to prevent membrane rupture and preterm labor.International journal of molecular sciences · 2014Article
- Tissue-specific differences in brain phosphodiesters in late-life major depression.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2014Article
- Polyunsaturated fatty acid associations with dopaminergic indices in major depressive disorder.The international journal of neuropsychopharmacology · 2014Article
- Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder.Pharmacological reviews · 2013Review
- Chronic treatment with anti-bipolar drugs causes intracellular alkalinization in astrocytes, altering their functions.Neurochemical research · 2012Review
- Epigenetic modifications in frontal cortex from Alzheimer's disease and bipolar disorder patients.Translational psychiatry · 2012Article
- Transcriptional repression of the α7 nicotinic acetylcholine receptor subunit gene (CHRNA7) by activating protein-2α (AP-2α).The Journal of biological chemistry · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Bipolar disorder (BD) is a severe psychiatric illness characterized by recurrent manic and depressive episodes, without a characteristic neuropathology or clear etiology. Drugs effective in BD target many key signaling pathways in animal and cell studies. However, their mode of action in the BD brain remains elusive. In the rat brain, some of the mood stabilizers effective in treating mania (lithium, carbamazepine, valproate) or depression (lamotrigine) in BD are reported to decrease transcription of cytosolic phospholipase A(2) and cyclooxygenase-2 and to reduce levels of AP-2 and NF-kappaB, transcription factors of the two enzymes. The anti-manic drugs also decrease arachidonic acid (AA) turnover in brain phospholipids when given chronically to rats. Thus, drugs effective in BD commonly target AA cascade kinetics as well as AA cascade enzymes and their transcription factors in the rat brain. These studies suggest that of BD is associated with increased AA signaling in the brain. Developing therapeutic agents that suppress brain AA signaling could lead to additional treatments for BD. In this review, we discuss the mechanisms of action of mood stabilizers and the effects of docosahexaenoic acid on AA cascade enzymes in relation to BD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.